Bliss GVS Pharma Limited published its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, in leading newspapers as mandated under SEBI Regulation 47. The pharmaceutical company's results were published on February 12, 2026, in English dailies 'The Economic Times & The Free Press Journal' and regional dailies 'Maharashtra Times & Navshakti'.

Financial Performance Overview

The company's financial performance for Q3FY26 showed mixed results across standalone and consolidated operations:

Nine-Month Performance Highlights

For the nine months ended December 31, 2025, the company demonstrated stronger consolidated performance:

On standalone basis, nine-month total income reached ₹55,268.72 lakh compared to ₹53,805.79 lakh in the previous year, while net profit increased to ₹6,445.19 lakh from ₹5,751.66 lakh.

Interim Dividend Declaration and Regulatory Compliance

The Board declared an interim dividend of 50%, equivalent to ₹0.50 per equity share of face value Re.1 each for financial year 2025-2026:

Publication and Disclosure Requirements

Under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published newspaper advertisements containing Quick Response Code (QR Code) and weblink to access complete financial results. The publication was made in both English and regional language newspapers to ensure wider accessibility.

Key Performance Metrics

The published results highlighted significant growth in consolidated operations for the nine-month period, with EBITDA reaching ₹11,959.65 lakh, representing a 13% increase. The company's equity share capital stood at ₹1,057.89 lakh as of December 31, 2025.

The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, read with relevant rules issued thereunder. Complete financial results are available on stock exchange websites www.bseindia.com and www.nseindia.com , as well as the company's official website.

Bliss GVS Pharma Limited has announced the incorporation of a wholly owned subsidiary in the Democratic Republic of Congo, marking another step in the company's international expansion strategy. The new subsidiary, THERALIFE PHARMA RDC PRIVATE LIMITED, was established in Kinshasa-Gombe through the company's existing Singapore operations.

Subsidiary Details and Structure

The incorporation was executed through Bliss GVS International PTE Ltd., Singapore, which is itself a wholly owned subsidiary of Bliss GVS Pharma Limited. This step-down subsidiary structure allows the company to expand its operations in the African pharmaceutical market.

Regulatory Compliance and Disclosure

The company has fulfilled its regulatory obligations by informing both the National Stock Exchange of India Ltd. and BSE Limited about this corporate development. The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key aspects of the regulatory filing include:

• Compliance with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024
• Adherence to SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023
• Complete disclosure as per Annexure-A requirements

Strategic Implications

The newly incorporated subsidiary operates within the pharmaceutical and health sector, aligning with Bliss GVS Pharma's core business activities. As this is a recent incorporation with a date of December 26, 2025, no turnover data is available for the entity. The establishment of this subsidiary demonstrates the company's commitment to expanding its presence in emerging African markets while maintaining its focus on the pharmaceutical industry.

The incorporation does not involve any acquisition costs or related party transactions, as it represents the creation of a new wholly owned subsidiary rather than the purchase of an existing entity. No governmental or regulatory approvals were required for this incorporation, and the process has been completed as announced.